Immune active cells with 4-1BB signal enhancement inhibit hepatitis B virus replication in noncytolytic manner.

[1]  M. Imamura,et al.  The Association between Serum Cytokine and Chemokine Levels and Antiviral Response by Entecavir Treatment in Chronic Hepatitis B Patients , 2018, Antiviral therapy.

[2]  S. Yan,et al.  Past, Current, and Future Developments of Therapeutic Agents for Treatment of Chronic Hepatitis B Virus Infection. , 2017, Journal of medicinal chemistry.

[3]  N. Shire.  Cure Strategies for Hepatitis B Virus: The Promise of Immunotherapy , 2017, Clinical pharmacology in drug development.

[4]  D. S. Li,et al.  NaHCO3 enhances the antitumor activities of cytokine-induced killer cells against hepatocellular carcinoma HepG2 cells , 2016, Oncology letters.

[5]  W. Ye,et al.  Augmented CD3(+)CD8(+) and CD3(+)CD56(-) cells in cytokine-induced killer cells cultured with engineered cells for costimulatory enhancement from heavily pretreated patients with solid tumor. , 2016, Cytotherapy.

[6]  Yuhree Kim,et al.  A randomized controlled trial on patients with or without adjuvant autologous cytokine-induced killer cells after curative resection for hepatocellular carcinoma , 2016, Oncoimmunology.

[7]  J. Yun,et al.  Adjuvant Cytokine-Induced Killer Cell Therapy Improves Disease-Free and Overall Survival in Solitary and Nonmicrovascular Invasive Hepatocellular Carcinoma After Curative Resection , 2016, Medicine.

[8]  Kai Wang,et al.  Crosstalk between innate and adaptive immunity in hepatitis B virus infection. , 2015, World journal of hepatology.

[9]  B. McMahon,et al.  Present and future therapies of hepatitis B: From discovery to cure , 2015, Hepatology.

[10]  E. Wherry,et al.  T cell exhaustion during persistent viral infections. , 2015, Virology.

[11]  Lin Zhao,et al.  The dual-functional capability of cytokine-induced killer cells and application in tumor immunology. , 2015, Human immunology.

[12]  X. Liu,et al.  T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance , 2015, Cell Death and Disease.

[13]  C. Ferrari.  HBV and the immune response , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[14]  J. Kim,et al.  Preclinical and clinical studies on cytokine-induced killer cells for the treatment of renal cell carcinoma , 2014, Archives of Pharmacal Research.

[15]  Y.-J. Ma,et al.  A Clinical Study of HBsAg‐Activated Dendritic Cells and Cytokine‐Induced Killer Cells During the Treatment for Chronic Hepatitis B , 2013, Scandinavian journal of immunology.

[16]  D. Campana,et al.  A Practical Approach to Immunotherapy of Hepatocellular Carcinoma Using T Cells Redirected Against Hepatitis B Virus. , 2013, Molecular therapy. Nucleic acids.

[17]  S. Rosenberg,et al.  Augmented Lymphocyte Expansion from Solid Tumors With Engineered Cells for Costimulatory Enhancement , 2011, Journal of immunotherapy.

[18]  E John Wherry,et al.  T cell exhaustion , 2011 .

[19]  Roger Williams,et al.  CD8+ T Cell Control of Hepatitis B Virus Replication: Direct Comparison between Cytolytic and Noncytolytic Functions , 2009, The Journal of Immunology.

[20]  Zheng Zhang,et al.  Transfusion of autologous cytokine-induced killer cells inhibits viral replication in patients with chronic hepatitis B virus infection. , 2009, Clinical immunology.

[21]  Zheng Zhang,et al.  Viral suppression correlates with dendritic cell restoration in chronic hepatitis B patients with autologous cytokine‐induced killer cell transfusion , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[22]  Lai Wei,et al.  Transfusion of multi-factors activated immune cells as a novel treatment for patients with chronic hepatitis B. , 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[23]  S. Rosenberg,et al.  Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. , 2005, The Journal of clinical investigation.

[24]  F. Finkelman,et al.  Prolonged Culture of Vaccine-Primed Lymphocytes Results in Decreased Antitumor Killing and Change in Cytokine Secretion , 2004, Cancer Research.

[25]  R. Purcell,et al.  CD8+ T Cells Mediate Viral Clearance and Disease Pathogenesis during Acute Hepatitis B Virus Infection , 2003, Journal of Virology.

[26]  G. Colucci,et al.  Non-cytolytic inhibition of hepatitis B virus replication in human hepatocytes. , 2001, Journal of hepatology.

[27]  Antonio Bertoletti,et al.  The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. , 2000 .

[28]  F. Chisari,et al.  Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. , 1996, Immunity.

[29]  R. Negrin,et al.  A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. , 1994, Journal of immunology.

[30]  M. Shapiro,et al.  Replicative intermediates of hepatitis B virus in HepG2 cells that produce infectious virions , 1988, Journal of virology.

[31]  T R Bender,et al.  Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. , 1985, The Journal of infectious diseases.